Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience

Kevin K. Veverka, James W Jakub, Christian Baum

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: In-transit cutaneous metastases occur in 5% to 10% of patients with melanoma. Recently, topical diphenylcyclopropenone (DPCP) has been described as a treatment option. OBJECTIVE: To evaluate efficacy of DPCP in treatment of in-transit cutaneous melanoma. METHODS: The authors retrospectively reviewed the records of 13 consecutive patients with in-transit metastases treated with topical DPCP between March 1, 2013, and January 31, 2017. The authors recorded the response of in-transit cutaneous melanoma lesions treated with DPCP measured by clinical examination. RESULTS: Among the 13 patients, 9 patients completed at least a 1-month course of DPCP treatment. Of these 9 patients, 6 (66.7%) maintained either stable disease or had a partial or complete regression, and 3 (33.3%) had progressive disease. Patients with less burden of disease (e.g., <15 lesions) responded more favorably than those with a greater burden of disease (e.g., >25 lesions or plaques). Both patients who received DPCP alone had progression of their cutaneous lesions. One patient who did not become sensitized to DPCP died within 2 months, and his anergy likely reflecting immense burden of disease. CONCLUSION: Topical DPCP is a low-cost, patient-applied treatment option for in-transit melanoma, most effective for patients with relatively low tumor burden and localized disease.

Original languageEnglish (US)
Pages (from-to)1501-1508
Number of pages8
JournalDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Volume44
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Tertiary Care Centers
Melanoma
Therapeutics
Skin
diphenylcyclopropenone
Neoplasm Metastasis
Tumor Burden
Costs and Cost Analysis

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

@article{2aa7d94988244670972c7e155f0c9ab8,
title = "Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience",
abstract = "BACKGROUND: In-transit cutaneous metastases occur in 5{\%} to 10{\%} of patients with melanoma. Recently, topical diphenylcyclopropenone (DPCP) has been described as a treatment option. OBJECTIVE: To evaluate efficacy of DPCP in treatment of in-transit cutaneous melanoma. METHODS: The authors retrospectively reviewed the records of 13 consecutive patients with in-transit metastases treated with topical DPCP between March 1, 2013, and January 31, 2017. The authors recorded the response of in-transit cutaneous melanoma lesions treated with DPCP measured by clinical examination. RESULTS: Among the 13 patients, 9 patients completed at least a 1-month course of DPCP treatment. Of these 9 patients, 6 (66.7{\%}) maintained either stable disease or had a partial or complete regression, and 3 (33.3{\%}) had progressive disease. Patients with less burden of disease (e.g., <15 lesions) responded more favorably than those with a greater burden of disease (e.g., >25 lesions or plaques). Both patients who received DPCP alone had progression of their cutaneous lesions. One patient who did not become sensitized to DPCP died within 2 months, and his anergy likely reflecting immense burden of disease. CONCLUSION: Topical DPCP is a low-cost, patient-applied treatment option for in-transit melanoma, most effective for patients with relatively low tumor burden and localized disease.",
author = "Veverka, {Kevin K.} and Jakub, {James W} and Christian Baum",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/DSS.0000000000001603",
language = "English (US)",
volume = "44",
pages = "1501--1508",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma

T2 - A Tertiary Referral Center Experience

AU - Veverka, Kevin K.

AU - Jakub, James W

AU - Baum, Christian

PY - 2018/12/1

Y1 - 2018/12/1

N2 - BACKGROUND: In-transit cutaneous metastases occur in 5% to 10% of patients with melanoma. Recently, topical diphenylcyclopropenone (DPCP) has been described as a treatment option. OBJECTIVE: To evaluate efficacy of DPCP in treatment of in-transit cutaneous melanoma. METHODS: The authors retrospectively reviewed the records of 13 consecutive patients with in-transit metastases treated with topical DPCP between March 1, 2013, and January 31, 2017. The authors recorded the response of in-transit cutaneous melanoma lesions treated with DPCP measured by clinical examination. RESULTS: Among the 13 patients, 9 patients completed at least a 1-month course of DPCP treatment. Of these 9 patients, 6 (66.7%) maintained either stable disease or had a partial or complete regression, and 3 (33.3%) had progressive disease. Patients with less burden of disease (e.g., <15 lesions) responded more favorably than those with a greater burden of disease (e.g., >25 lesions or plaques). Both patients who received DPCP alone had progression of their cutaneous lesions. One patient who did not become sensitized to DPCP died within 2 months, and his anergy likely reflecting immense burden of disease. CONCLUSION: Topical DPCP is a low-cost, patient-applied treatment option for in-transit melanoma, most effective for patients with relatively low tumor burden and localized disease.

AB - BACKGROUND: In-transit cutaneous metastases occur in 5% to 10% of patients with melanoma. Recently, topical diphenylcyclopropenone (DPCP) has been described as a treatment option. OBJECTIVE: To evaluate efficacy of DPCP in treatment of in-transit cutaneous melanoma. METHODS: The authors retrospectively reviewed the records of 13 consecutive patients with in-transit metastases treated with topical DPCP between March 1, 2013, and January 31, 2017. The authors recorded the response of in-transit cutaneous melanoma lesions treated with DPCP measured by clinical examination. RESULTS: Among the 13 patients, 9 patients completed at least a 1-month course of DPCP treatment. Of these 9 patients, 6 (66.7%) maintained either stable disease or had a partial or complete regression, and 3 (33.3%) had progressive disease. Patients with less burden of disease (e.g., <15 lesions) responded more favorably than those with a greater burden of disease (e.g., >25 lesions or plaques). Both patients who received DPCP alone had progression of their cutaneous lesions. One patient who did not become sensitized to DPCP died within 2 months, and his anergy likely reflecting immense burden of disease. CONCLUSION: Topical DPCP is a low-cost, patient-applied treatment option for in-transit melanoma, most effective for patients with relatively low tumor burden and localized disease.

UR - http://www.scopus.com/inward/record.url?scp=85057211895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057211895&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000001603

DO - 10.1097/DSS.0000000000001603

M3 - Article

C2 - 29985863

AN - SCOPUS:85057211895

VL - 44

SP - 1501

EP - 1508

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 12

ER -